Tidemark’s TG Therapeutics TGTX Stock Holding History

Tidemark’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-9	Closed	-$154	–	730
2023 Q4	$154	Buy	+9	New	+$105	﹤0.01%	678

Other funds holding TGTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Tidemark's TGTX Position: Q1 2024 in Review

Tidemark sold out of TG Therapeutics (TGTX) in Q1 2024, closing a stake of 9 shares — an estimated $154 sold.

Tidemark first reported a position in TGTX in Q4 2023 and held it in 1 quarter. The position peaked at $154 in Q4 2023. 243 funds tracked by Wall St. Rank hold TGTX as of Q1 2024.

Tidemark reported no remaining TG Therapeutics position as of Q1 2024 after selling out during the quarter.
Tidemark sold 9 TG Therapeutics shares in Q1 2024, an estimated $154.
Tidemark first reported a position in TG Therapeutics in Q4 2023 and held it in 1 quarter.
Tidemark's TG Therapeutics position peaked at $154 in Q4 2023.
243 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2024.

Based on Tidemark's 13F filing for Q1 2024, filed 13 May 2024.